logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Erlotinib (Tarceva) for non-small cell lung cancer, locally advanced and/or metastatic, EGFR mutation positive – first line

< Back

Erlotinib (Tarceva) for non-small cell lung cancer, locally advanced and/or metastatic, EGFR mutation positive – first line

Drugs

Cancer and Palliative Care

August 2010


Erlotinib hydrochloride (Tarceva, CP-358774, OSI-774, R-1415) is an orally-active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets the underlying molecular mechanisms involving oncogenes and tumour suppressor genes that play a critical role in the conversion of normal cells into a cancerous state. It is anticipated that erlotinib will be used as a substitute for existing treatment. Erlotinib is administered orally in a continuous regimen at 150mg daily.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

PDF Report



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts